Effects of PYCR1 on prognosis and immunotherapy plus tyrosine kinase inhibition responsiveness in metastatic renal cell carcinoma patients

BACKGROUND: Immunotherapy plus tyrosine kinase inhibitor (IO-TKI) has become the first-line management for metastatic renal cell carcinoma (RCC), despite the absence of biomarkers. Recently, pyrroline-5-carboxylate reductase 1 (PYCR1) and proline metabolism have been reported regulatory roles in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xianglai, Wang, Ying, Hu, Xinyu, Zhu, Yanjun, Wang, Jiajun, Guo, Jianming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404727/
https://www.ncbi.nlm.nih.gov/pubmed/37517099
http://dx.doi.org/10.1016/j.neo.2023.100919

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404727/
https://www.ncbi.nlm.nih.gov/pubmed/37517099
http://dx.doi.org/10.1016/j.neo.2023.100919

Ejemplares similares